Trial · NCT01271712
Participant flow26
How many started, completed or left each group, period by period.
1 to 20 of 26
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double Blind Treatment | STARTED | Regorafenib (Stivarga, BAY73-4506) | 133 | |
| Double Blind Treatment | STARTED | Placebo First, Then Option of Open Label Regorafenib Treatment | 66 | |
| Double Blind Treatment | Participants Received Treatment | Regorafenib (Stivarga, BAY73-4506) | 132 | |
| Double Blind Treatment | Participants Received Treatment | Placebo First, Then Option of Open Label Regorafenib Treatment | 66 | |
| Double Blind Treatment | COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 91 | |
| Double Blind Treatment | COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 58 | |
| Double Blind Treatment | NOT COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 42 | |
| Double Blind Treatment | NOT COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 8 | |
| Open Label Treatment | STARTED | Regorafenib (Stivarga, BAY73-4506) | 91 | |
| Open Label Treatment | STARTED | Placebo First, Then Option of Open Label Regorafenib Treatment | 58 | |
| Open Label Treatment | COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 0 | |
| Open Label Treatment | COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 0 | |
| Open Label Treatment | NOT COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 91 | |
| Open Label Treatment | NOT COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 58 | |
| Safety Follow-up | STARTED | Regorafenib (Stivarga, BAY73-4506) | 118 | |
| Safety Follow-up | STARTED | Placebo First, Then Option of Open Label Regorafenib Treatment | 52 | |
| Safety Follow-up | COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 97 | |
| Safety Follow-up | COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 37 | |
| Safety Follow-up | NOT COMPLETED | Regorafenib (Stivarga, BAY73-4506) | 21 | |
| Safety Follow-up | NOT COMPLETED | Placebo First, Then Option of Open Label Regorafenib Treatment | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01271712/flow